{"entity":{"id":"paper-dart-nivolumab-ipilimumab-nec-patel-ccr-2020","kind":"paper","name":"DART (SWOG 1609): nivolumab plus ipilimumab in rare tumours, non-pancreatic neuroendocrine neoplasms cohort","aka":[],"tldr":"In a basket trial of rare cancers, dual immunotherapy shrank tumours in about a quarter of patients with non-pancreatic neuroendocrine neoplasms, almost all of them high-grade carcinomas, giving an immunotherapy option for a disease with few treatments.","summary":"Neuroendocrine cohort of the phase 2 DART basket trial: 32 patients with non-pancreatic neuroendocrine neoplasms treated with nivolumab plus ipilimumab.\n\nObjective response was 25 percent overall and 44 percent in high-grade neuroendocrine carcinoma, with no responses in low- or intermediate-grade tumours; median progression-free survival was 4 months and overall survival 11 months.","asOf":"2026-09-17","links":[{"label":"Clin Cancer Res 2020","url":"https://doi.org/10.1158/1078-0432.CCR-19-3356"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/31969335/"}],"tags":[],"related":[],"cancers":["extrapulmonary-nec"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-cancer-research"],"dependsOn":[],"notes":[],"journal":"Clinical Cancer Research","year":2020,"doi":"10.1158/1078-0432.CCR-19-3356","pmid":"31969335","authors":"Patel SP, Othus M, Chae YK, et al.","paperType":"observational","findings":["Objective response 25 percent overall; 44 percent in high-grade neuroendocrine carcinoma.","No responses in grade 1 to 2 neuroendocrine tumours."],"whatItMeans":"Nivolumab plus ipilimumab is a guideline-listed option for extrapulmonary neuroendocrine carcinoma after platinum chemotherapy, whereas well-differentiated tumours do not respond.","caveats":["Very small cohort; responses were not always durable.","A subsequent expansion cohort reported lower response rates."],"changedPractice":true,"participants":32},"route":"/key-papers/paper-dart-nivolumab-ipilimumab-nec-patel-ccr-2020/","neighbours":{"cancer":[{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/"}],"journal":[{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/"}]}}